SITC Resource Library

Presentation slides and video from the 2023 Advances in Cancer Immunotherapy^™ Series: A Focus on MSI-high/TMB-high Cancers & Biomarkers were presented in-person and virtually on October 13, 2023 in New York, NY.

Program Organizers

• Andrea Cercek, MD – Memorial Sloan Kettering Cancer Center
• Benoit Rousseau, MD, PhD – Memorial Sloan Kettering Cancer Center
• Robert Samstein, MD, PhD – Icahn School of Medicine at Mount Sinai Tisch Cancer Institute

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Program Learning Objectives

• Discuss biomarkers in clinical use with cancer immunotherapies and their relevance to the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers.

• Summarize recent updates in the use of biomarkers for cancer immunotherapies and of cancer immunotherapy for MSI-H/TMB-H cancers including emerging toxicities and management.

• Implement the use of biomarkers to select appropriate immunotherapy for cancers, including MSI-H/TMB-H cancers.

• Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers.

You can view the program agenda here.

Please note on-demand recordings are not available for continuing education credits.